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Abstract 
Photodynamic therapy, in its various applications, represents the focused combination of 
electromagnetic radiation, a chemical – usually a dye - capable of its absorption and conversion, and 
oxygen to provide cytotoxicity (cell-killing).  The effect has been known for over a century and there 
is considerable clinical use in terms of its application to various cancers.  However, the antimicrobial 
properties of the technology – which are considerable – have received only a lukewarm reception by 
healthcare providers and the possibilities for tropical disease therapy are mainly unexplored.  This is 
particularly vexatious given both the inexpensive nature of the photosensitisers and light sources 
available in conjunction with the lack of conventional forward progress in widespread diseases such 
as leishmaniasis, trypanosomiasis and tuberculosis in the Developing World. 
The following review therefore covers the use - or potential use – of the photodynamic approach in 
this area, mainly with reference to tropical diseases haǀiŶg ĐurreŶt ͚ŶegleĐted͛ status, aĐĐordiŶg to 
the World Health Organisation. 
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Introduction 
Light–activated or photoantimicrobial drugs are not widely appreciated by healthcare organisations 
in the developed, affluent nations.  It is of little surprise, therefore, that the use of these agents in 
ǁhat is terŵed ͚TropiĐal MediĐiŶe͛ ďǇ suĐh ŶatioŶs is ŵaiŶlǇ uŶkŶoǁŶ.  This is a highly ironic 
situation. 
21st Century drug discovery is heavily reliant on in silico design, but many of the products of this 
process still carry the imprint of earlier, experimentally-derived molecules.  The earliest drugs, 
particularly in the field of infection control, were dyes.  Indeed it was the efforts of chemists such as 
Paul Ehrlich in searching for chemical cures for ͚tropiĐal͛ diseases – typically malaria and African 
trypanosomiasis (sleeping sickness) - which gave birth to rational synthetic drug discovery and 
chemotherapy [1].  The line of descent can be drawn clearly between drug molecules aimed at 
various disorders of the central nervous system, such as depression, anxiety or schizophrenia, or 
those aimed at diseases of warmer climes such as malaria, and early, standard biological dyes and 
stains.  Some of these structural similarities can be seen in Figure 1. 
 
 
 
Figure 1.  Conventional drugs derived from dyes. 
 
As noted, pioneering scientists such as Ehrlich experimented with the then recently-available aniline 
dyes to demonstrate selectivity in different cell types, work which led to the demonstration of 
selective inactivation of certain cells viewed under the microscope.  Eventually, in 1891, Ehrlich 
could report human cures, with two sailors infected with falciparum malaria being cured with the 
dye methylene blue [2].  The early antimicrobial (intentionally anti-syphilitic) drug Salvarsan – 
EhrliĐh͛s ŵost faŵous invention – was derived from experimentation on azoic dyes, the arsenic 
atoms in the drug which endow its toxicity, replacing the original azoic nitrogens (Figure 1).  Ehrlich 
and his students, of whom there were many, developed what became known as dye therapy to 
cover several tropical diseases and led to the development of what are now thought of as 
conventional drugs for malaria and African trypanosomiasis, or sleeping sickness (e.g. chloroquine, 
Suramin and melarsoprol, respectively, Figure 1) [3]. 
Once effective colourless drug molecules had been introduced, tissue colouration caused by the use 
of dyes became an undesirable side-effect. Consequently use of dye-therapy then diminished. The 
introduction of more conventional antimicrobial drugs, such as the penicillins, further diminished the 
use of dyes, and by the mid-20th century most were considered obsolete. 
Given the amount of experimentation concerning therapeutic dyes around the turn of the previous 
century, it is not surprising that other scientific directions were also followed. Thus it was discovered 
that dyes could be useful as indicators of the physical environment (pH, oxidation-reduction) and of 
particular analytes – the presence of specific metal ions, for example [4]. 
In 1900, Oskar Raab was a student working for two supervisors in Munich, von Tappeiner and 
Jesionek.  In his experiments on unicellular organisms, Raab noted that the synthetic dyes he was 
using –acridine and several xanthene dyes - caused one species, Paramecium caudatum, to stop 
moving when exposed to light.  This stillness was later shown to be cell death and the observation 
was the first reported example of what was subsequently termed Photodynamy [5].  It should be 
Ŷoted that ‘aaď͛s superǀisors were later to take these findings and demonstrate a similar effect 
against animal tumours [6]. The occurrence of reports of the photodynamic effect was sporadic over 
the next sixty years, with a significant rise in activity in response to drug-resistant, mainly bacterial, 
infections in the healthcare sector during the early 1990s. 
In terms of tropical diseases of Homo sapiens, the greatest contribution of dye therapy has been the 
provision of antimalarials.  Due to the Japanese occupation of the Dutch East Indies from 1942, 
Allied forces in the South-East Asian theatre required alternatives to quinine, and this was supplied 
first by the aminoacridine mepacrine and later by the closely related 4-aminoquinoline analogue 
chloroquine (Figure 1) [7].  Members of the armed forces taking the acridine dye derivative 
mepacrine often presented a jaundiced appearance due to the persistence of the bright yellow 
acridine drug in the skin [8].  Chloroquine is a colourless compound and is thus – apparently - non-
staining.  However, chloroquine photosensitivity is a well-established side-effect of the drug, due to 
the skin absorption of ultraviolet wavelengths in sunlight [9]. 
As ĐaŶ ďe seeŶ froŵ Figure 1, the geŶealogǇ of ŵoderŶ aŶtiŵalarials ŵaǇ ďe traĐed ďaĐk to EhrliĐh͛s 
use of methylene blue in the late 19th Century.  Improved derivatives of the original phenothiazine 
dye were synthesised by chemists at IG Farben in the inter-war period, having basic side chains (e.g. 
Paludenblau, Figure 1).  However, the staining effects were not avoided and this was one of the 
reasons that the search moved on to acridines and quinolines [10].  Perhaps surprisingly, methylene 
blue itself is again being used as a conventional antimalarial for the treatment of juvenile disease 
where there is chloroquine resistance, for example in sub-Saharan Africa, since 2005 [11].  Of course, 
the disadvantage of staining the patient becomes less important in areas with high rates of 
childhood mortality and with the continued efficacy of the dye. 
Thus, while the conventional treatment of some tropical diseases was supplied initially by dyes, very 
few now remain in use.  However, the established selectivity of a range of dye molecules for various 
organisms implicated in these neglected diseases suggests a firm basis for the development of a 
different therapeutic approach, utilising this selectivity and another dye property, that of 
photosensitisation. 
 
Photosensitisers and the photodynamic effect. 
‘aaď͛s initial discovery involving the inactivation of paramecia occurred when he employed the 
xanthene dyes (among others) with illumination.  Had he used the xanthene dye fluorescein, there 
would have been no killing effect.  Photosensitisers are a subset of dyes and, as this example shows, 
even closely structurally-related compounds may differ significantly in behaviour. 
Photosensitisation in organic dyes relies on their absorption of light energy and their ability to utilise 
this in chemical or physical reaction – either in the transfer of an electron (Type I photosensitisation) 
or energy (Type II photosensitisation) to oxygen molecules in close proximity, to produce reactive 
oxygen species, such as singlet oxygen, the hydroxyl radical and superoxide (Figure 2).  Deactivation 
pathways exist, such as fluorescence – i.e. the release of the energy (or most of it) by the excited-
state dye in a single emission – which is what would have been observed by Raab had he used 
fluorescein. 
 
 
Figure 2.  Photosensitisation pathways.  Key A – absorption of light; T – thermal deactivation of the 
singlet excited state; F – fluorescence deactivation; P – phosphorescence deactivation of the triplet 
state; ISC – inter-system crossing. 
 The difference in behaviour here lies in the extra stability of the excited-state molecule - e.g. eosin Y, 
Figure 3 - stabilised, in fact, by the four bromine atoms - fluorescein has none - attached to the 
chromophore.  This is known as the Heavy Atom Effect and similar behaviour can be seen in other 
xanthene photosensitisers erythrosine (four iodine atoms) and rose Bengal (four iodine atoms and 
four chlorine atoms, Figure 3).  Similar effects are seen in the phenoxazine and phenothiazine (or 
phenoselenazine) dyes, the former type being photodynamically inactive whereas the other classes, 
containing lower period sulphur or selenium atoms are generally very efficient photosensitisers [12]. 
 
 
Figure 3.  Photosensitisers and the Heavy Atom Effect. Key: 1O2 – efficiency of singlet oxygen 
production [13,14]. 
 
On illumination with the correct wavelength radiation, photosensitisers are thus able to interact to a 
far greater extent with their environment than do other dyes, and if this illumination occurs when 
the molecule is either inside or closely associated with a cell, the ensuing chemical reaction (or 
reactions) can produce cell damage or death, particularly in simple cells (Figure 2).  This was the 
process first reported by Raab for paramecia. 
What was not apparent at the time of Raaď͛s disĐoǀerǇ ǁas that the Ŷoǁ estaďlished therapeutiĐ 
dye methylene blue is also a photosensitiser, normally working via the Type II pathway and 
producing the highly reactive molecule singlet oxygen [15].  This is significantly toxic to simple 
microbial cells.  Other standard microbiological dyes which are also photosensitisers include crystal 
violet, acriflavine and neutral red [16]. 
Consequently, what became apparent from the sporadic literature output concerning 
photosensitisers during the early-mid 20th Century was that much of the pathogenic threat to 
humans and their animals could be very simply disarmed without conventional drugs, at least in the 
laboratory. 
In order to produce cell killing/inactivation by this method there must be interaction of the target 
cell, photosensitiser and light.  In the laboratory setting this is straightforward, but is obviously a 
somewhat more complex process when the target is inside an individual host.  For this reason the 
clinical application of photosensitisers is, at least at present, confined to topical or local infection.  
The use of endoscopy/fibre optics allows light delivery to remote sites, with the loci of infection 
being identified and tracked via ultrasound and X-ray.  IŶfeĐted sites oŶ the ďodǇ͛s eǆterŶal surfaces 
or shallow orificial sites are obviously far more accessible and can be treated superficially. 
There is thus an excellent basis for the application of the photodynamic approach to the cure of 
infectious disease.  The requisite conversion from bench to bedside has not proved so simple, 
however, and usually for reasons other than robust scientific rationale. 
 
Tropical Disease and Neglected Status 
As noted above, the term tropical disease is one employed mainly by those resident outside the 
countries located around the central band of the globe.  However, for many years the term also 
contained a significant implication of the inability of such countries to deal with diseases such as 
malaria or trypanosomiasis.  Given that many of these stricken countries were also normally unable 
to support a western-style system of healthcare, they were equally incapable of paying the 
enormous drug fees demanded by large pharmaceutical concerns.  Consequently, research into 
tropical medicines decreased, in many cases ceasing altogether.  Interest was somewhat rekindled 
initially by the human immunodeficiency virus – acquired immunodeficiency syndrome (HIV-AIDS) 
pandemic, and then when it became apparent that increasing globalisation was promoting the 
emergence of tropical disease outside the tropics.  In both cases, the excellent medical practice of 
widespread organised blood collection for therapeutic use, suddenly became recognised as a 
conduit for previously unencountered or, certainly in the case of HIV-AIDS, unknown diseases [17]. 
The Drugs for Neglected Diseases initiative (DNDi) began in 2003, recognising the need with 
particular reference to African and American trypanomiasis, leishmaniasis, malaria, paediatric HIV 
and helminth (worm) infections such as schistosomiasis [18].  However, the World Health 
OrgaŶisatioŶ͛s list of ŶegleĐted tropiĐal diseases is ĐoŶsideraďlǇ loŶger, aŶd seǀeŶteeŶ of these haǀe 
been prioritised (Table 1).  It will be noted that the WHO list does not include malaria, tuberculosis 
or HIV-AIDS. 
  
 Disease Causative Organism Type Route 
Buruli ulcer Mycobacterium ulcerans Bacterium  
(Acid Fast) 
Aquatic bugs 
Chagas’ disease Trypanosoma cruzi Protozoan Reduviid bug bite 
Chikungunya Virus Enveloped virus Mosquito bite 
Dengue Virus Enveloped virus Mosquito bite 
Dranunculiasis Guinea worm Worm Water flea bite 
Echinococcosis Echinococcus spp. Tapeworm Animal faeces 
Hansen’s Disease ;LeprosyͿ Mycobacterium leprae Bacterium  
(Acid-Fast) 
Infected aerosol 
Human African 
Trypanosomiasis 
Trypanosoma spp. Protozoan Tsetse fly bite 
Leishmaniasis Leishmania spp. Protozoan Sandfly bite 
Lymphatic filariasis 
(Elephantiasis) 
Roundworm, e.g. 
Wucheria bancrofti 
Worm Mosquito bite 
Onchocerciasis (River 
Blindness) 
parasitic worm Worm Black fly 
Rabies Lyssavirus Enveloped virus Animal bite 
Schistosomiasis S. haematobium 
flatworm 
Worm infected water (via 
urinary tract) 
Soil-transmitted 
helminthiases 
Helminths Worm Faecal 
Trachoma Chlamydia trachomatis Bacterium 
(Gram-negative) 
Physical contact 
Trematodiasis Flatworms Worm Molluscs (food) 
Taeniasis/Cysticercosis Tapeworms Worm Food 
Yaws Treponema pallidum 
pertenue 
Bacterium 
(Gram-negative) 
Skin contact 
    
Table 1.  Alphabetical WHO list of neglected tropical diseases [19] 
 
Infection and Transmission 
Most people – in the northern hemisphere, for example - thinking of tropical disease normally 
imagine insect bites as the cause.  This may be some way from the truth, especially given that many 
such diseases involve the life cycle of a parasite, the incidental bite occurring at some time during 
this cycle.  However, in addition, some diseases are transmitted directly between humans, or 
between humans and animals, neither requiring the involvement of an insect.  Others are caused 
directly by nematodes or worms.  Furthermore, the causative organisms in the various diseases 
considered here might be bacteria, viruses or protozoa.  Such is the overwhelming publicity 
accorded to malaria, that mosquito bites and plasmodia (the causative protozoal class) dominate the 
public consciousness as far as this field is concerned. 
As has been noted, the photodynamic approach requires the combination of photosensitiser, oxygen 
and light to produce the desired cell killing effect.  From a therapeutic point of view, this is 
somewhat more complex than conventional drug administration (i.e. tablet or injectable) and has a 
significant impact on the type of infection which might be treated photodynamically.  Thus, for 
example, malaria is a blood-borne disease and is treated with systemic drugs - i.e. affecting the 
whole body - which fight the parasite in the bloodstream (some also target the liver stage of the 
disease).  Clearly it would be difficult to illuminate the whole of the circulatory system, so 
photodynamic attack in this respect is not currently possible in the clinic.  However, other diseases 
have a localised tissue stage, often in the region of the original bite etc., and this constitutes an ideal 
presentation for the local application of photosensitiser and light. 
Given that most pathogenic organisms appear in the bloodstream during disease - whether tropical 
or otherwise – the use of donated blood and products derived from this should obviously be avoided 
if collected during the period of illness, but this should also be the case in the run-up to illness, when 
the individual is asymptomatic.  While this may seem straightforward for individuals who are 
diseased, it is far less so in the pre-symptomatic period.  Furthermore, there are those who will 
donate blood in the full knowledge that they have an infection – although this is more often the case 
where payments are made by the collecting agency in order to encourage donation. 
Finally, there is the phenomenon of the emerging disease – i.e. infection caused by hitherto 
unknown, and therefore unlooked-for, pathogens being introduced into the blood supply.   Certainly 
this was the case in the 1980s/early 90s with what is now called the human immunodeficiency virus 
(HIV) [18].  Far more stringent examination and monitoring of the blood supply – haemovigilance - 
has resulted [20]. 
Photosensitising dyes have an important part to play in the protection of the blood supply, including 
that of blood products, such as the clotting factors used in the treatment of haemophilia. The 
photodynamic effect can be carried out on isolated blood fractions, such as plasma or platelets [21], 
and this is covered in the various disease sections below.  Clearly, this is a somewhat more indirect 
approach to the problem of tropical disease, not being an attack on the disease syndrome itself, but 
rather on its transmission.  However, it is no less important for that and, as part of the development 
of more integrated, better-funded and organised blood collection in many of the countries where 
such diseases are endemic, it would go a long way towards significantly decreasing the resulting 
morbidity and mortality. 
 
Identifying Potential Approaches 
Table 1 provides information on aetiology for the various diseases listed.  Given that the 
photodynamic approach to infectious disease depends on the presentation of the target organism, 
these aetiologies can inform the type of application and when this might be employed during the life 
cycle of that particular microbe.  However, it should be remembered – unsurprisingly, since 
photoantimicrobial research is incredibly poorly funded in richer, developed countries – that there is 
often little hard evidence for a positive effect and much of this can therefore only be provided by 
extrapolation. 
In terms of attack, there are three, basic modalities: direct application to the infected host 
(topical/local); photodynamic disinfection of blood products containing the target organism; 
photodynamic disinfection of waterborne targets (environmental approach).  A simple decision tree 
is shown in Figure 4.  A further consideration here must also be that the use of the photodynamic 
approach endows some benefit over the status quo.  This may be in overcoming conventional 
resistance mechanisms, conserving conventional drugs to avoid resistance development or providing 
a less damaging alternative (for example, natural photosensitisers versus chlorine in water 
disinfection). 
 
 
 
Figure 4.  Decision tree to help determine if the photodynamic approach is advantageous. 
 
Clearly, it is not the case that photosensitisers are the answer to tropical disease, but there is 
considerable potential in a number of presentations, as noted in the sections below.  A similar 
situation pertains in infection control in developed countries, but with little uptake currently on the 
part of healthcare providers [22].  While this does not augur well for the present argument, it may 
be that medical positions here are rather less well entrenched in the light of neglected status. 
The following sections deal with the potential use of photosensitisers either directly to the host, in 
the treatment of blood/tissue products or of colonised water. 
 
 
 
 
Topical/Local Therapy 
Acceptable photosensitisers 
The therapeutic application of xenobiotic ;͚foreigŶ͛Ϳ substances to the host organism should 
demonstrate toxicity to the target(s) but not the host.  While this is rarely possible – there are 
usually side effects, but these are mostly negligible in commonly-used medications – there is an onus 
on the developer of the therapy to demonstrate minimal host damage.  Consequently, in the early 
21st Century, there are very few photosensitisers which are licensed for use in humans or animals 
[23].  In many ways, this has been the main frustration for groups involved in photosensitising drug 
discovery over the past quarter century or, to put it another way, the costs involved in satisfying 
toxicity criteria for new compounds are unattractive to most funding agencies.  Consequently, the 
strength of legislative bodies is such that there is little option but to make initial essays with 
acceptable photosensitisers to provide a baseline, safe therapeutic approach and on these grounds 
to seek support for improved photosensitiser development [24]. 
Currently, the only photoantimicrobial dyes licensed for clinical use – i.e. with light activation - are 
the phenothiazinium derivatives methylene blue and toluidine blue and the heptacyanine dye 
indocyanine green [25].   Many others have been synthesised based on both of these dyes classes, as 
well as others, but little has resulted in terms of movement towards the clinic.  There are further dye 
class examples which have seen previous conventional use as antimicrobials, such as the 
triphenylmethanes and aminoacridines, as well as food dyes [23].  These have the potential for re-
examination in the search for candidates with sufficient photoactivity and lack of host toxicity.  
Similarly, there are naturally-occurring photosensitisers, such as riboflavin (vitamin B2) and the 
perylenequinonoid hypericin, from the plant Hypericum perfloratum ;St JohŶ͛s WortͿ [26]. 
 
Approaches 
As mentioned above, there are various presentations (i.e. the combinations of 
symptoms/appearance indicating the disease) within the field of tropical diseases where the target 
organisms are localised to a relatively small volume, rather than being systemically spread.  Similarly, 
others may be more extensive or diffuse but located on the host exterior (skin/hide).  Potentially, 
these presentation are amenable to the photodynamic approach, since both the photosensitising 
dye and activating light can be applied directly to the site of infection, internal disease being 
targeted via direct photosensitiser instillation and illumination via fibre optics. 
 
Bacterial infection 
Since much of the drive for the inclusion of photoantimicrobials in infection control has come from 
(usually) academic researchers in the developed world, it is not surprising that there is a 
considerable literature covering photobactericides, particularly screened against conventionally-
resistant hospital bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) [27].  
Following 25 years of research in this area the range of susceptible bacteria is wide, covering both 
Gram types, as would be expected, given the non-selective oxidation caused at the target.  However, 
in terms of the available dyes, cationic nature is essential for broad-spectrum activity, since anionic 
and neutral dyes are less active against Gram-negative bacteria, due to the negatively-charged outer 
membrane of this class [28].  It should be remembered, of course, that the bacteria mentioned also 
constitute a threat to health in less-developed countries. 
Of the tropical diseases identified as bacterial in Table 1, two are Gram-negative (Chlamydia 
trachomatis and Treponema pallidum pertenue) while two are mycobacterial (Mycobacterium 
ulcerans and M. leprae), and are therefore not stained by the Gram system.  Although tuberculosis 
does not have neglected status, it also has a mycobacterial aetiology (M. tuberculosis).  While Gram-
negative bacteria are susceptible to cationic photosensitisers, far less research has been carried out 
on mycobacteria [29]. 
Yaws is caused by the entry into the skin, via a cut or abrasion, of the bacterium T. pallidum 
pertenue, which can lead to tissue ulceration or bone infection of left untreated.  Current therapy 
utilises long-acting penicillins or other standard antibacterials [30].  However, there is certainly an 
argument against conventional drug use, where available, due to the possibility of drug resistance 
development.  Direct application to the original wound using a cationic photoantimicrobial, such as 
methylene blue or toluidine blue and superficial/interstitial illumination with red light should be 
sufficient to eradicate the causative organism.  The combination of methylene blue and red light has 
also been shown to cure bone infection (osteomyelitis) [31]. 
Infection of the eye by Chlamydia trachomatis, normally referred to as trachoma, causes damage to 
the underside of the eyelid.  Untreated, this can lead to greater eye damage and, ultimately, 
blindness.  Standard treatment is, again, with conventional antibacterials such as a tetracycline [32].  
Localised infection beneath the eyelid might seem a difficult presentation for the photodynamic 
approach; however, the thinness of the eyelid means that it should be transparent to red light.  
Consequently, instillation of methylene blue or toluidine blue into the eye with a short incubation 
time should allow uptake by the chlamydia, and this would be followed by superficial illumination. 
It should be noted that both T. pallidum and C. trachomatis are known to be selectively stained by 
methylene blue [33,34]. 
In terms of mycobacteria, the absence of Gram-staining capability might suggest weaker potential 
photosensitiser interaction, but this is not the case.  While the exterior of mycobacteria is made up 
of long-chain alkanoic acids (mycolic acids), this still constitutes a negatively-charged region to which 
cations will, logically, bind.  It has been shown that each of M. smegmatis in vitro and M. fortuitum,  
M. marinum in vivo are photoinactivated using methylene blue [35-37].  This also provides an 
excellent basis for the investigation of its activity against M. tuberculosis, and the presence of 
multiply drug-resistant (MDR) strains should provide little defence against reactive oxygen species 
(ROS), and singlet oxygen in particular [29].  It is expected that the photosensitiser would be 
administered using a bronchoscope, while illumination would be either bronchoscopic or superficial, 
depending on the site of the lesion inside the lung.  ConverselǇ, although HaŶseŶ͛s disease ;leprosǇͿ 
has been known as a devastating human disease for thousands of years, the site of the infecting M. 
leprae as a locus of disease is still not firmly established.  Its presence in the peripheral nerves, 
leading to lack of sensation in, and eventual damage, infection and loss of, the extremities, would 
represent a considerable challenge to the photodynamic approach. 
 Protozoal infection 
In terms of localised infection, the targets here with most potential are cutaneous leishmaniasis and 
Chagas͛ disease, both offering relatively easily accessible lesions, and both having parasites which 
are susceptible to photodynamic attack [38].   The inactivation of Leishmania donovani  and 
Trypanosoma cruzi has been ably demonstrated by various groups in the area of blood 
photodecontamination (q.v.), using a range of photosensitisers [39-41].  However, it would be 
expected – as in the other areas discussed - that those with clinical pedigree would be employed in 
any therapeutic introduction.  Methylene blue would thus be the front runner, along with crystal 
violet which was used conventionally until relatively recently for trypanosomal blood 
decontamination (i.e. without light activation) in South America [42,43]. 
 
Little is known concerning the effects of local photodynamic treatment on other protozoa, once 
again reflecting the paucity of research in this area.  As with L. donovani and T. cruzi, and as 
discussed below, malarial parasites of the Plasmodium genus are very easily killed by photoactivated 
methylene blue.  Consequently, it would be difficult to argue against similar predicted outcomes 
with other species of similar parasite.  Indeed, it is notable that the photodynamic effect of 
methylene blue against T. brucei was first reported in 1938 [44]. 
 
Worm infection 
As mentioned above, the concentration of photosensitiser required to kill a colonising 
worm/nematode would be relatively high due to the greater complexity of the organism compared 
to single-cell targets.  However, individuals having undergone worm removal through the skin often 
suffer further from post-operatiǀe ďaĐterial iŶfeĐtioŶ ǁhiĐh, iŵportaŶtlǇ, ŵaǇ delaǇ the iŶdiǀidual͛s 
return to work.  Such infected sites are obvious targets for photodynamic disinfection as discussed 
elsewhere. 
 
Blood product decontamination 
The use of human blood, either directly in replacement or in fractionation to supply absent or under-
provided protein factors is highly valuable in the saving or improvement of human life.  However, its 
proper regional/national organisation is a considerable and expensive undertaking.  Consequently, 
many of the areas subject to the diseases considered by the present discussion do not have access to 
the national blood service-type organisation enjoyed by most developed countries.  Where this is 
possible, or is being developed, there is a part to be played by photosensitising dyes. 
 
Human blood is a complex fluid, made up of both cellular and non-cellular fractions, the latter also 
being a complex mixture of proteins and other biological materials.  Donated blood can be 
fractionated (red cells, platelets, plasma, clotting factors) or used whole, but there is obvious 
potential for infection transmission (transfusion-transmission infection, TTI) if the original donation 
is pathogenically colonised, as explained above.  As far as tropical disease is concerned, the major 
pathogens are bacterial, viral or protozoal in nature [45] (Table 2), although filarial transmission is 
also known [46], and this requires a very broad-spectrum approach, yet one which does not damage 
the various blood fractions contained. 
 
Disease Causative 
Organism 
Presentation Evidence 
Bacterial    
Buruli ulcer Mycobacterium 
ulcerans 
Ulcer, skin & soft tissue 
Donated blood 
In vivo/in vitro vs. 
Mycobacterium spp. 
[29] 
HaŶseŶ͛s Disease 
(Leprosy) 
Mycobacterium 
leprae 
Infected digits/appendages In vivo/in vitro vs. 
Mycobacterium spp. 
[27] 
Trachoma Chlamydia 
trachomatis 
Eyes 
Donated blood 
In vitro vs. Chlamydia 
spp. [34] 
Yaws Treponema 
pallidum 
pertenue  
Ulcer, skin & soft tissue, bone 
Donated blood 
In vitro vs. Treponema 
spp. [33] 
    
Protozoal    
Chagas͛ disease Trypanosoma 
cruzi 
Ulcer, skin & soft tissue 
Donated blood 
In vitro vs. 
Trypanosoma spp. [68-
70] 
Human African 
Trypanosomiasis 
Trypanosoma 
spp. 
Donated blood In vitro vs. 
Trypanosoma spp. [44] 
Cutaneous 
leishmaniasis 
Leishmania spp. Ulcer, skin & soft tissue 
Donated blood 
In vitro vs. Leishmania 
spp. [67] 
    
Viral    
Chikungunya Alphavirus 
(enveloped) 
Donated blood In vitro vs. virus [73] 
Dengue Flavivirus 
(enveloped) 
Donated blood In vitro vs. virus [73] 
Rabies Lyssavirus 
(enveloped) 
Donated blood In vitro vs. virus [75] 
    
Table 2.  Suitable presentations for photodynamic attack 
 
A further complication pertains to the exact situation of the infecting organism in cellular fractions, 
since this might be intracellular, cell-associated (externally) or diffuse in the suspending medium 
(plasma). Logically, the ease of targeting increases in the same order.  For example, the use of 
methylene blue and red light to inactivate dengue virus would be relatively straightforward in 
plasma, but is much less effective in red cell concentrates due to the fact that the dye does not 
readily cross into the cell interior [47]. Indeed, methylene blue causes red cell membrane damage on 
illumination [48].  Alternative approaches – e.g. ultraviolet illumination, ultrafiltration or solvent-
detergent treatment – all have drawbacks, usually relating to specificity and collateral damage [49]. 
The use of dyes for the disinfection of donated blood was suggested in 1955 [50], again, methylene 
blue being the dye in question due to its considerable prior use in humans.  This did not become a 
reality until the 1990s, but since then many millions of plasma units have been treated in Europe 
[51]. 
As noted above, the HIV-AIDS pandemic, commencing in the late 1970s, led to a re-examination of 
blood donation processes to ensure that viral contamination could not occur.  In turn, the ensuing 
protocols introduced gave protection against many other pathogens.  The very broad-spectrum 
range provided by the photodynamic approach obviously covers most current pathogenic bacteria, 
fungi, viruses and protozoa, including emerging pathogens of these types.  However, this is most 
effective in the treatment of non-cellular blood products (Figure 5).  The Zika virus is of considerable 
concern currently, mainly due to resulting birth defects, and this can be transmitted via donated 
blood [52]. However, being an enveloped virus, of the Flavivirus family (like the yellow fever virus, 
for example) Zika should be susceptible to the photodynamic approach, using methylene blue or 
riboflavin - the first report of the photodynamic inactivation of yellow fever virus (with methylene 
blue) occurred as far back as 1934 [53]. The range of blood component-susceptible pathogens 
relevant to the current argument is shown in Table 3, again demonstrating both the dearth of 
research in this area and the potential for new protocol development. 
  
  
 
Figure 5.  Pathogen photoinactivation process for red cell and plasma fractions.  In each case, the 
fraction is incubated with a photosensitiser (e.g. methylene blue or riboflavin, step (a)) and then 
illuminated (b).  Clearly the process is more straightforward in the absence of cellular material. 
 
  
 Pathogen Photosensitiser Fraction 
Leishmania donovani Riboflavin Plasma / Platelets [67] 
 
Trypanosoma cruzi 
 
 
 
 
Methylene blue 
 
Riboflavin 
 
Crystal violet 
 
Phthalocyanines 
 
 
Plasma [68] 
 
Plasma / Platelets [69] 
 
Whole blood [70] 
 
Red cells [71] 
 
 
Plasmodium falciparum Silicon phthalocyanine (Pc4) Red cells [72] 
 
Chikungunya Methylene blue 
 
Riboflavin 
Plasma  [73] 
 
Plasma / Platelets [74] 
 
Dengue Methylene blue Plasma [73] 
 
Rabies virus Methylene blue, proflavine Plasma [75] 
 
Table 3.  Reported blood component photodisinfection capabilities versus causes of various tropical 
diseases 
As can be seen, there are currently few dyes suitable for use in blood product decontamination, 
however wide the range for methylene blue, and this is certainly an area which requires proper 
examination via organised research.  Riboflavin (vitamin B2) and the psoralen (furanocoumarin) 
derivative amotosalen (Table 3, Figure 6) should not be counted as conventional dyes, although they 
do act as photosensitisers.  The scientific argument for riboflavin use lies in its lack of toxicity, being 
an essential human vitamin [54].  Conversely, amotosalen is an entirely synthetic agent which has 
been shown to have very low toxicity in mammals and works via photochemically crosslinking 
pathogenic DNA or RNA [55].  Similarly to the methylene blue process, further insurance against 
toxicity is provided by the removal of the psoralen by a post-illumination adsorption step (i.e. before 
transfusion). 
The exploitation and development of these few photosensitised/photochemical processes has been 
carried out commercially by MacoPharma (methylene blue / Theraflex system), Terumo BCT 
(riboflavin / Mirasol) and the Cerus Corporation (amotosalen / Intercept) [56-58]. 
 
 
  
Figure 6.  Photosensitisers in current use for pathogen inactivation. 
 
Water purification 
The use of the photodynamic approach to pathogen inactivation is most effective with simple cell 
types, rather than complex, or multicellular organisms.  Logically, the greater the target complexity, 
the more damaging events are required for its inactivation.  Consequently, for example, simple 
prokaryotic bacteria are far more susceptible to the approach than are healthy eukaryotic cells, such 
as those found in the human or animal host.  Many tropical pathogens have a relatively simple, 
aqueous stage which, in some cases leads to infections due to far more complex organisms, such as 
the larval flatworms associated with schistosomiasis [59].  A similar situation often pertains to the 
arthropod vectors of disease, such as mosquito eggs and larvae.  These more rudimentary targets 
can be combatted in their aqueous environment using a photodynamic approach which can be seen 
as a modification of the blood product decontamination method discussed in the previous section. 
Clearly, the treatment of a large volume of colonised water offers a different prospect to that of a 
plasŵa ďlood ďag.  Hoǁeǀer, at ďoth eǆtreŵes, the produĐt ŵust ďe ͚ĐleaŶ͛ eŶough for huŵaŶ use 
in the absence both of pathogenic contamination and of the treating photosensitiser to prevent any 
post-treatment toxicity.  While this is achieved in blood product disinfection by small adsorption 
tubes, such an approach for large-scale work would be unwieldy and expensive.  In addition, it would 
be a far ͚greeŶer͛ approaĐh to be able to re-use the photosensitiser for subsequent water 
treatments.  This might be achieved by attaching the photosensitiser to a solid matrix, either fixed 
within the decontamination chamber or, perhaps in granular form, moved throughout the medium 
during the agitation associated with the illumination process.  Photosensitiser matrices would be 
retained via filtration of the treated water.  Such a scenario is shown in Figure 7. 
 
 Figure 7. Potential water photodecontamination process. 
 
The provision of potable water is essential to health and liberal estimates put the annual global 
mortality associated with the lack of this resource at 502,000 diarrhoeal deaths [60].  Given a robust 
photosensitising system and, in many cases, a very reliable and free (solar) light source, the 
photodynamic approach to water purification should be a relatively straightforward proposition, 
particularly in the case of associated enteric bacterial pathogens such as Escherichia coli, Shigella 
and Vibrio spp., given their established susceptibilities [61-63].  Industrial water treatment has been 
carried out using the inorganic photosensitising pigment anatase (TiO2) [64], but organic 
photosensitisers offer a wider range of visible absorption – anatase uses ultraviolet.  In addition, 
given that the photosensitisers would be retained during the water processing, toxicity requirements 
would presumably be less stringent. 
 
Do it yourself 
Much of the preceding commentary concerning the use of photoactivable agents to combat 
infectious disease pertains to photosensitisers and light sources which would require purchase by 
healthcare agencies in the afflicted regions.  In this respect, the same fiscal problems would arise 
which currently inhibit the provision of conventional drugs, although to a lesser degree, given the 
relatively inexpensive nature of established photosensitisers such as methylene blue and crystal 
violet.  In other words, developing nations would remain dependent on multinational corporations 
from the industrialised nations for their healthcare. 
The synthesis of the dyes, materials or equipment proposed would not be of great cost to the end-
user, if it were possible for these to be produced within the regions requiring them, possibly with the 
advice or collaboration of overseas academics or industrialists with prior experience in the 
preparation and application of photoantimicrobials.  Such local development/production would also 
allow the tailoring of therapy to suit the local environmental conditions. 
A regular, metred amount of light is preferable for safe therapy, e.g. from a laser or light-emitting 
diode (LED) array.  However, as noted above, since the diseases under discussion are mainly suffered 
in equatorial regions, there is also a plentiful and reliable supply of solar radiation.  Clearly, this 
might be used where metred light is not available to promote the photodynamic treatment of local 
infection, but care must be taken both to match the radiation to the photosensitiser and to avoid 
side effects.  The former criterion is relatively straightforward, since the photosensitisers available 
for clinical use have well-known absorption profiles.  For example, methylene blue, toluidine blue 
and crystal violet all possess intense, long-wavelength absorption bands (600-670 nm region) which 
overlap with the long-wavelength region of the solar spectrum.  Side effects might arise, for instance 
in the treatment of localised cutaneous infection, from the exposure of healthy tissue to the 
photosensitiser and sunlight, but this can be avoided by covering tissue in the peripheral regions 
(e.g. with black surgical tape), so that the infected region is exposed precisely.  In addition, the 
amount of light incident on the target area can be measured or modelled and solar exposure times 
recommended. 
Furthermore, many plants are known to contain photosensitising chemicals [65].  It is possible to 
decoct mixtures of e.g. psoralens and coumarins from various plant parts and to apply these as 
photodynamic, though less regulated, preparations to infected sites.  This approach has been used 
since ancient times – e.g. in Egyptian and Ayurvedic medicine – for the treatment of skin disease 
[66].  However, since such compounds are not strictly dyes, they fall outwith the current area of 
review. 
 
Conclusions 
Tropical medicine is under-funded in the 21st Century.  Pressures usually generated in the more 
fortunate parts of the global economy mean that health spending per capita in many countries 
blighted by the diseases covered here is a small fraction of that available in developed nations.  
Consequently, effective alternative approaches to the treatment of neglected illnesses such as 
ĐutaŶeous leishŵaŶiasis or Chagas͛ disease offer ĐoŶsideraďle sĐope for the iŵproǀeŵeŶt of health, 
particularly given the decreased costs involved.  There is much to be discovered concerning the use 
and general applicability of photosensitisers in tropical medicine and there are clearly a number of 
diseases which are suited to being treated by this approach. 
Given the lack of properly organised research and development possible in most countries of the 
Developing World, it is incumbent on richer economies – preferably in firm partnership with these 
countries – to deliver suitable therapeutics.  Such action would be particularly fitting, given that it 
was the pursuit of the chemotherapy of tropical disease that allowed the discoveries which led to 
the formation of the pharmaceutical industry. 
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